Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2012.0241


Everolimus added to aromatase inhibitors for improving hormone-receptor-positive breast cancer outcomes.

Eleftheria Ignatiadou, MD.

Affiliation: Dr. Eleftheria Ignatiadou, Department of Surgery, University Hospital of Ioannina, Ioannina, TK 45110, Greece.


Since there is no abstract available we provide the first paragraph.
Activation of the mammalian target of rapamycin (mTOR) intracellular signalling pathway can be one of the causes to endocrine therapy resistance in breast cancer. Everolimus, a mTOR inhibitor, has shown antitumor activity in previous studies. Baselga and colleagues [1] report now in NEJM the results of a phase 3 randomized trial in which everolimus was added to exemestane in patients with hormone-receptor-positive advanced breast cancer. The potential to overcome resistance to aromatase inhibitor by adding everolimus in standard therapy of breast is discussed.

(Citation: Gastric & Breast Cancer 2012; 11(3): 163-165).

You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €35 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 10 July 2012